We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 126.00 | 1.04% | 12,188.00 | 12,186.00 | 12,190.00 | 12,266.00 | 12,054.00 | 12,194.00 | 161,565 | 09:57:52 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.72 | 188.91B |
From May 2021 to May 2024
By Sabela Ojea
AstraZeneca PLC said Monday that its Ultomiris drug has been recommended for marketing authorization in the European Union by the EMA Committee for Medicinal Products for Human Use, or CHMP.
The pharmaceutical major said the use of the drug has been expanded to include children and adolescents with paroxysmal nocturnal haemoglobinuria.
The opinion is based on results from an Ultomiris phase 3 trial, which showed an established efficacy and safety profile with reduced treatment burden for children with PNH and their families, the FTSE 100 listed company added.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
July 26, 2021 02:27 ET (06:27 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
